With approval from local officials in Ireland now in hand, Shire said work on a $400 million biologics plant can begin.
The rare disease drugmaker announced today that with the final planning step complete, it will begin recruiting for the 400 jobs the new plant is expected to require.
“We are pleased to have met this important milestone as we move forward in preparation to start building our new manufacturing plant,” Tim Kelly, Shire senior VP of biologics, said in a statement.
The construction on the facility, which will be able to produce clinical through commercial scale products, is expected to begin shortly and be complete in 2019. It is being built on a 120-acre site in Piercetown, County Meath, about 20 miles from Dublin.
Shire is a much larger company than it was when it announced the the plant last spring. In June it completed its $32 billion deal to acquire Baxalta. Now the company is in the process of merging Baxalta into its operations.
CEO Flemming Ornskov said in August that Shire now believes it can cut about $700 million in annual savings from the combined companies instead of the $500 million it initially promised investors. He said that about 20% will come from manufacturing as the company eliminates redundancies and finds ways to leverage the drugmakers’ combined scale of operations.
By Eric Palmer
Source: Fierce Pharma
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.